Citadel Advisors
QNCX icon

Citadel Advisors’s Quince Therapeutics QNCX Stock Holding History

Citadel Advisors’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.51K Buy
+173
New +$34.7K ﹤0.01% 12825
2025
Q2 		– Sell
-16
Closed -$4.12K – 14599
2025
Q1 		$4.12K Sell
16
-4
-20% -$1.22K ﹤0.01% 13914
2024
Q4 		$7.48K Buy
+20
New +$6.01K ﹤0.01% 13737
2024
Q3 		– Sell
-2
Closed -$300 – 15042
2024
Q2 		$300 Buy
+2
New +$361 ﹤0.01% 14038
2023
Q3 		– Sell
-5
Closed -$1.5K – 14952
2023
Q2 		$1.5K Sell
5
-15
-75% -$4.67K ﹤0.01% 13919
2023
Q1 		$6.24K Sell
20
-105
-84% -$20.5K ﹤0.01% 13822
2022
Q4 		$15.9K Sell
125
-11
-8% -$1.84K ﹤0.01% 13303
2022
Q3 		$36K Sell
136
-16
-11% -$6.09K ﹤0.01% 11813
2022
Q2 		$67K Sell
152
-311
-67% -$220K ﹤0.01% 11741
2022
Q1 		$573K Sell
463
-195
-30% -$265K ﹤0.01% 9070
2021
Q4 		$1.66M Buy
658
+31
+5% +$189K ﹤0.01% 6667
2021
Q3 		$11.5M Sell
627
-497
-44% -$7.9M ﹤0.01% 2832
2021
Q2 		$11.9M Sell
1,124
-246
-18% -$2.06M ﹤0.01% 2812
2021
Q1 		$9.87M Sell
1,370
-16
-1% -$115K ﹤0.01% 2976
2020
Q4 		$7.7M Buy
+1,386
New +$12.3M ﹤0.01% 3001

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors's QNCX Position: Q1 2026 in Review

Citadel Advisors sold out of Quince Therapeutics (QNCX) in Q1 2026, closing a stake of 780 shares — an estimated $157K sold.

Citadel Advisors first reported a position in QNCX in Q3 2019 and held it in 18 quarters. The position peaked at $16M in Q2 2020. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Citadel Advisors reported no remaining Quince Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 780 Quince Therapeutics shares in Q1 2026, an estimated $157K.
  • Citadel Advisors first reported a position in Quince Therapeutics in Q3 2019 and held it in 18 quarters.
  • Citadel Advisors's Quince Therapeutics position peaked at $16M in Q2 2020.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.